UCB SA (ETR:UNC)
Germany · Delayed Price · Currency is EUR | Market Cap | 38.95B -12.8% |
| Revenue (ttm) | 8.52B +24.5% |
| Net Income | 2.19B +64.7% |
| EPS | 11.32 +64.9% |
| Shares Out | n/a |
| PE Ratio | 17.75 |
| Forward PE | 16.06 |
| Dividend | 1.02 (0.50%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 161 |
| Open | 201.60 |
| Previous Close | 205.60 |
| Day's Range | 201.60 - 203.30 |
| 52-Week Range | 201.60 - 287.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 25, 2027 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial StatementsNews
Why United Community Banks (UCB) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out.
UCB SA Transcript: Investor update
BIMZELX continues to gain global traction, especially in HS, with robust long-term data supporting its efficacy and safety. Early and first-line use leads to superior outcomes, and quality of life improvements are significant. Access is expanding, and while new oral therapies are emerging, injectables remain preferred due to efficacy.
Ucb SA at Bank of America Global Healthcare Conference Transcript
Ucb SA at Bank of America Global Healthcare Conference Transcript
UCB SA Transcript: J.P. Morgan European Healthcare CEO Call Series
A decade of growth is underway, fueled by strong execution, strategic acquisitions, and innovation in immunology and neurology. BIMZELX leads with unique efficacy and expanding access, while the pipeline advances in atopic dermatitis, severe epilepsy, and T-cell engager therapies.
UCB SA Transcript: Bank of America Global Healthcare Conference
The session highlighted robust H1 growth, upgraded guidance, and a focus on long-term innovation. BIMZELX remains the primary growth driver, with expanding indications and strong access strategies. Early-stage pipeline assets and targeted commercial execution underpin confidence in sustained growth and margin expansion.
UCB (UCBJY) Upgraded to Buy: Here's Why
UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why United Community Banks (UCB) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out.
UCB's CIMZIA Receives FDA Breakthrough Therapy Designation In Pregnant Women With APS
(RTTNews) - UCB SA (UCBJY), announced that the U.S. FDA has granted Breakthrough Therapy Designation to CIMZIA (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes i...
UCB Looks 7.2% Overvalued on GF Value™ as Dividend Sustainability Remains Key
UCB Looks 7.2% Overvalued on GF Value™ as Dividend Sustainability Remains Key
United Community Banks Names Tom Speir CFO To Succeed Jefferson Harralson
(RTTNews) - United Community Banks, Inc. (UCB) Wednesday announced the appointment of Tom Speir as executive vice president and chief financial officer. Speir is a banking executive with financial, me...
UCB SA Earnings Call Transcript: H1 2026
First-half 2026 saw net sales rise 23% to EUR 4.1 billion, driven by five growth products now over half of revenue. Upgraded guidance reflects strong BIMZELX momentum, new peak sales target above EUR 7 billion, and robust pipeline expansion through acquisitions and clinical advances.
UCB SA Earnings release: H1 2026
UCB SA released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
UCB SA Quarterly report: H1 2026
UCB SA has published its H1 2026 quarterly earnings report on July 30, 2026.
UCB SA Slides: H1 2026
UCB SA has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
UCB shares fall despite guidance upgrade as investors question earnings quality
Belgian biopharmaceutical group UCB raised its 2026 earnings guidance on Thursday, but its shares fell more than 8% as investors focused on weaker-than-expected sales of flagship drug Bimzelx and qu...
UCB SA Transcript: Investor update
BE BOLD demonstrated bimekizumab's statistically significant superiority over risankizumab in joint outcomes for psoriatic arthritis, with sustained efficacy and a safety profile consistent with prior studies. The results are expected to influence clinical guidelines, prescribing practices, and payer dynamics, supporting bimekizumab's positioning as a first-line therapy.
UCB SA Slides: Investor update
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.